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Introduction {#bdd2003-sec-0001}
============

Glucagon‐like peptide‐1 (GLP‐1) is an incretin hormone secreted from the gastrointestinal tract in response to food intake. The active form of GLP‐1 stimulates insulin secretion in a blood glucose‐dependent manner while simultaneously suppressing glucagon secretion [1](#bdd2003-bib-0001){ref-type="ref"}. The active form of GLP‐1 is rapidly degraded and inactivated by dipeptidyl peptidase‐4 (DPP‐4). DPP‐4 inhibitors prevent the degradation of GLP‐1, and thus increase the blood concentrations of the active form of GLP‐1.

Several DPP‐4 inhibitors are now prescribed in clinical practice for the treatment of type 2 diabetes mellitus. DPP‐4 inhibitors have a variety of chemical structures, and are classified as either peptide mimetic compounds, which are designed by modifying the structure of the peptide substrate (anagliptin [2](#bdd2003-bib-0002){ref-type="ref"}, saxagliptin [3](#bdd2003-bib-0003){ref-type="ref"}, teneligliptin [4](#bdd2003-bib-0004){ref-type="ref"} and vildagliptin [5](#bdd2003-bib-0005){ref-type="ref"}), or non‐peptide mimetic compounds, which are designed by modifying the structures of compounds identified in random screening assays (alogliptin [6](#bdd2003-bib-0006){ref-type="ref"}, linagliptin [7](#bdd2003-bib-0007){ref-type="ref"} and sitagliptin [8](#bdd2003-bib-0008){ref-type="ref"}) [9](#bdd2003-bib-0009){ref-type="ref"} (Figure [1](#bdd2003-fig-0001){ref-type="fig"}). Because of differences in their chemical structures, there are also differences in their binding modes [10](#bdd2003-bib-0010){ref-type="ref"}, DPP‐4 inhibitory activity [2](#bdd2003-bib-0002){ref-type="ref"}, [11](#bdd2003-bib-0011){ref-type="ref"} and physical properties, including *C*log*P*, an index of lipophilicity (Table [1](#bdd2003-tbl-0001){ref-type="table-wrap"}). It has been reported that DPP‐4 inhibitors vary greatly with respect to their plasma concentration--time profiles and elimination pathways in humans, and that these differences may necessitate dose adjustments owing to drug interactions and renal impairment [12](#bdd2003-bib-0012){ref-type="ref"}, [13](#bdd2003-bib-0013){ref-type="ref"}.

![Chemical structures of DPP‐4 inhibitors](BDD-37-142-g001){#bdd2003-fig-0001}

###### 

Characteristic features of DPP‐4 inhibitors

  Drug            Binding subsites[a](#bdd2003-note-0001){ref-type="fn"}   *C*log*P* [b](#bdd2003-note-0002){ref-type="fn"}   pKa[c](#bdd2003-note-0003){ref-type="fn"}   *V* ~ss~ (l/kg)[d](#bdd2003-note-0004){ref-type="fn"} \[Reference\]   IC~50~ (nmol/l)[e](#bdd2003-note-0005){ref-type="fn"} \[Reference\]
  --------------- -------------------------------------------------------- -------------------------------------------------- ------------------------------------------- --------------------------------------------------------------------- ---------------------------------------------------------------------
  Alogliptin      S~1~, S~2~, S'~1~                                        0.99                                               8.5                                         3.5 [19](#bdd2003-bib-0019){ref-type="ref"}                           4.9 [11](#bdd2003-bib-0011){ref-type="ref"}
  Anagliptin      --                                                       0.55                                               6.7                                         0.68 [2](#bdd2003-bib-0002){ref-type="ref"}                           3.8 [2](#bdd2003-bib-0002){ref-type="ref"}
  Linagliptin     S~1~, S~2~, S'~1~, S'~2~                                 1.91                                               1.9, 8.6                                    50.3 [23](#bdd2003-bib-0023){ref-type="ref"}                          0.6 [11](#bdd2003-bib-0011){ref-type="ref"}
  Saxagliptin     S~1~, S~2~                                               −0.03                                              7.3                                         5.2 [20](#bdd2003-bib-0020){ref-type="ref"}                           6.3 [11](#bdd2003-bib-0011){ref-type="ref"}
  Sitagliptin     S~1~, S~2~, S~2~ extensive                               0.69                                               7.7                                         8.8 [25](#bdd2003-bib-0025){ref-type="ref"}                           10.3 [11](#bdd2003-bib-0011){ref-type="ref"}
  Teneligliptin   S~1~, S~2~, S~2~ extensive                               2.24                                               1.7, 3.8, 7.3                               8.9                                                                   1.9 [11](#bdd2003-bib-0011){ref-type="ref"}
  Vildagliptin    S~1~, S~2~                                               0.69                                               7.6                                         8.6 [26](#bdd2003-bib-0026){ref-type="ref"}                           29.2 [11](#bdd2003-bib-0011){ref-type="ref"}

These binding subsites were determined from the co‐crystal structures of the inhibitors with DPP‐4 by x‐ray crystallography [10](#bdd2003-bib-0010){ref-type="ref"}.

These values were calculated using the PCModels in Daylight software version 4.93 (<http://www.daylight.com>/).

As stated on the manufacturer\'s interview form.

The volume of distribution at steady state (*V* ~ss~) was calculated after intravenous administration to rats.

Median inhibitory concentration against DPP‐4.

Teneligliptin is a DPP‐4 inhibitor that was approved for the treatment of type 2 diabetes mellitus in 2012 in Japan and in 2014 in Korea [14](#bdd2003-bib-0014){ref-type="ref"}, [15](#bdd2003-bib-0015){ref-type="ref"}. In humans, teneligliptin is eliminated by hepatic metabolism mediated by cytochrome P450 3A4 or flavin‐containing monooxygenase 3, or excreted from the kidney as the unchanged drug [16](#bdd2003-bib-0016){ref-type="ref"}. Teneligliptin is thus removed via several elimination routes. Variations in the exposure of patients to teneligliptin with renal and hepatic disorders were 1.68‐fold and 1.59‐fold higher than those in healthy subjects [17](#bdd2003-bib-0017){ref-type="ref"}, [18](#bdd2003-bib-0018){ref-type="ref"}; thus, a dose adjustment was not required, even for patients with renal or hepatic disorders.

This study investigated the tissue distribution of teneligliptin in rats during the preclinical development of teneligliptin, and compared the tissue distribution profiles of teneligliptin and other currently available DPP‐4 inhibitors to examine differences in their tissue distribution. The tissue distribution and physicochemical properties differ between the currently available DPP‐4 inhibitors, as shown in this study and other studies; therefore, their tissue distribution might be associated with their potential pleiotropic effects beyond their glucose‐lowering properties.

Materials and Methods {#bdd2003-sec-0002}
=====================

Objectives {#bdd2003-sec-0003}
----------

Four independent preclinical studies were performed with the following objectives. Study 1: to determine the change in tissue concentration of teneligliptin in rats, and to quantify the distribution and the disappearance of teneligliptin in each tissue. Study 2: to obtain *in vivo* images visualizing the tissue distribution of teneligliptin and to verify the results of study 1. Study 3: to determine the role of DPP‐4 in the tissue distribution of teneligliptin. Study 4: to determine the relative concentrations of radiolabeled teneligliptin and its major metabolites in plasma and the kidney, which showed the highest concentration of teneligliptin in studies 1--3.

Materials {#bdd2003-sec-0004}
---------

\[^14^C\]Teneligliptin (specific radioactivity 1.03--1.08 MBq/mg and radiochemical purity 98.5%--99.2%) was synthesized by Sekisui Medical Co., Ltd (Tokyo, Japan). The chemical structure of teneligliptin and the position of the radiolabel are shown in Figure [2](#bdd2003-fig-0002){ref-type="fig"}. All other chemicals were of analytical grade or higher purity, and were obtained from commercial suppliers.

![Chemical structure of \[^14^C\]teneligliptin. The position of the ^14^C radiolabel on teneligliptin is indicated by an asterisk](BDD-37-142-g002){#bdd2003-fig-0002}

Animals {#bdd2003-sec-0005}
-------

The study protocol was reviewed and approved by the Institutional Animal Care and Use Committee of Mitsubishi Chemical Safety Institute Ltd (now LSI Medience Corporation, Tokyo, Japan). For studies 1, 2 and 4, male Sprague--Dawley rats (Crj:CD(SD)IGS; hereafter, SD rats) were purchased from Charles River Japan (Kanagawa, Japan). For study 3, male wild‐type Fischer rats (F344/Jcl; hereafter, wild‐type rats) and DPP‐4‐deficient male rats (F344/DuCrlCrlj; hereafter, DPP‐4‐deficient rats) were purchased from CLEA Japan (Shizuoka, Japan) and Charles River Japan, respectively. The rats were housed with a 12‐h light/dark cycle and controlled temperature and humidity. The rats were fasted from the evening before the dosing day to about 5 h after administration, but were given drinking water during this time.

Tissue distribution of radioactivity in SD rats (study 1) {#bdd2003-sec-0006}
---------------------------------------------------------

Male SD rats were given a single oral dose of 1 mg/1.67 MBq/kg \[^14^C\]teneligliptin. Rats were euthanized at 0.5, 5, 12, 24, 72 and 168 h after administration (*n* = 4/time), and the following tissues were collected: blood, plasma, brain, pituitary, medulla oblongata, eyeball (bilateral), submaxillary gland, thyroid, spinal cord (neck), thymus, heart, lung, liver, adrenal (bilateral), kidney (bilateral), spleen, pancreas, prostate, testis (bilateral), epididymis, seminal vesicle, aorta (thoracic), skin (around the armpit), skeletal muscle (femoral), bone (femur), bone marrow (femoral), perirenal white adipose tissue, brown adipose tissue, mesenteric lymph nodes, stomach, small intestine, cecum and large intestine (except for the cecum). The entire blood sample was immediately transferred to a test tube with heparin sodium as an anticoagulant and gently inverted several times. One portion (200 μl) of the blood was set aside as a blood sample. The remaining blood was centrifuged (4 °C, 10 min at 1870 × *g*) and the supernatant (plasma) was retained. The other tissues were washed with physiological saline, wiped with pieces of filter paper to remove saline, and weighed. The samples were stored at −20 °C until used to measure radioactivity.

Whole‐body autoradiography of SD rats (study 2) {#bdd2003-sec-0007}
-----------------------------------------------

Male SD rats were given a single oral dose of 1 mg/1.67 MBq/kg \[^14^C\]teneligliptin and were euthanized at 0.5, 24 or 168 h after administration (*n* = 1/time). The animals were immediately frozen in a dry ice/acetone bath. The frozen body was embedded in about 4%--5% (*w*/*v*) carboxymethylcellulose solution and sliced using a cryomicrotome. The resulting frozen thin sections (40 μm thick) were collected on adhesive tape and freeze‐dried in the cryomicrotome. The sections were exposed for 72 h in a lead‐shielded box. The radiogram on the imaging plate was scanned using a bio‐imaging analyser (BAS‐2000II, Fujifilm Corporation, Tokyo, Japan) to obtain radioluminograms.

Whole‐body autoradiography of wild‐type or DPP‐4‐deficient rats (study 3) {#bdd2003-sec-0008}
-------------------------------------------------------------------------

Male wild‐type or DPP‐4‐deficient rats were given a single oral dose of 1 mg/1.60 MBq/kg \[^14^C\]teneligliptin. Tail vein blood samples were collected at 0.5, 24, 36 and 48 h after administration (*n* = 1/time). After the blood sampling, each rat was euthanized, frozen in a dry ice/acetone bath and embedded in about 4%--5% (*w*/*v*) carboxymethylcellulose solution together with the calibration blood samples of four different concentrations of \[^14^C\]teneligliptin. Tissue sections (40 μm thick) were prepared using a cryomicrotome, collected on adhesive tape and freeze‐dried in the cryomicrotome. Radioluminograms were obtained as described for study 2. The radioluminograms obtained in study 3 were analysed using an RLG analysing system (Multi Gauge Ver.2.2, Fujifilm Corporation, Tokyo, Japan) with the blood calibration standards to determine the radioactivity concentration in each tissue.

Metabolite profiles in plasma and kidney (study 4) {#bdd2003-sec-0009}
--------------------------------------------------

Male SD rats were given a single oral dose of 1 mg/1.60 or 1.67 MBq/kg \[^14^C\]teneligliptin. The rats were euthanized (*n* = 2 or 4/time) at 0.5 and 5 h after administration for plasma sampling or at 0.5, 24 and 72 h after administration for kidney sampling. The kidney was weighed and homogenized in a 4‐fold volume of phosphate‐buffered saline. The plasma or kidney homogenates were mixed in a 2‐fold volume of extraction solvent (acetonitrile for plasma, methanol for kidney homogenate), shaken and centrifuged (4 °C, 5 min at 1870 × *g*) to obtain the supernatant. The pellet was extracted with the same volume of extraction solvent, shaken and centrifuged (4 °C, 5 min at 1870 × *g*). The obtained supernatants were combined and evaporated under a nitrogen gas stream. Then, 5% acetonitrile was added to the dry residue and the mixture was injected into a high‐performance liquid chromatography (HPLC) system (LC‐10Avp HPLC system; Shimadzu, Kyoto, Japan) with an in‐line radioactivity detector (Flo‐One Radiomatic 610TR; PerkinElmer, Waltham, MA). Chromatographic separation was performed on an HPLC column (Capcell Pak C18 UG120, 5 μm, 4.6 mm × 250 mm; Shiseido, Tokyo, Japan) with gradient elution. The mobile phase consisted of 10 m[m]{.smallcaps} ammonium acetate/formic acid (100:0.5 \[*v*/*v*\], solvent A) and acetonitrile/10 m[m]{.smallcaps} ammonium acetate/formic acid (80:20:0.5 \[*v*/*v*/*v*\], solvent B). The gradient was started with 10% solvent B for 15 min, and the amount of solvent B was increased linearly to 20% over 20 min, 30% over 5 min and 70% over 10 min, followed by holding at 70% for 10 min. The elution sites of ^14^C‐labeled metabolites were confirmed by reference to HPLC‐ultraviolet chromatograms of unlabeled standard of teneligliptin and metabolites M1, M2, M3, M4 and M5 [16](#bdd2003-bib-0016){ref-type="ref"}.

Measurement of radioactivity {#bdd2003-sec-0010}
----------------------------

Radioactivity was determined using a liquid scintillation counter (LSC, Tri‐Carb 2300TR, PerkinElmer Life and Analytical Sciences, Waltham, MA) with quenching correction for the transformed spectral index of an external standard in accordance with the manufacturer\'s instructions. Each sample was measured once for 5 min. The net count was determined by subtracting the background count, which was obtained by measuring the scintillation cocktail alone for 5 or 10 min, from the gross count for each sample. The detection limit of radioactivity was set at twice the background counts per minute (cpm).

Data analysis {#bdd2003-sec-0011}
-------------

The radioactivity concentrations in tissues were analysed using WinNonlin (Ver. 4.1 or 5.2, Certara, St Louis, MO) and the elimination half‐life (*t* ~1/2~) was calculated using the values for the last three quantifiable time‐points after administration.

Reference values for marketed DPP‐4 inhibitors {#bdd2003-sec-0012}
----------------------------------------------

The reference values for other marketed DPP‐4 inhibitors were obtained from previous studies [19](#bdd2003-bib-0019){ref-type="ref"}, [20](#bdd2003-bib-0020){ref-type="ref"}, [21](#bdd2003-bib-0021){ref-type="ref"} and the Japanese Common Technical Documents submitted to the Pharmaceuticals and Medical Devices Agency (PMDA) [22](#bdd2003-bib-0022){ref-type="ref"}, [23](#bdd2003-bib-0023){ref-type="ref"}, [24](#bdd2003-bib-0024){ref-type="ref"}, [25](#bdd2003-bib-0025){ref-type="ref"}, [26](#bdd2003-bib-0026){ref-type="ref"}.

Results {#bdd2003-sec-0013}
=======

Tissue distribution of radioactivity in SD rats (study 1) {#bdd2003-sec-0014}
---------------------------------------------------------

Figure [3](#bdd2003-fig-0003){ref-type="fig"} shows the radioactivity concentration--time profiles in tissues, and Table [2](#bdd2003-tbl-0002){ref-type="table-wrap"} shows the tissue radioactivity concentrations in fasted SD rats given a single oral dose of 1 mg/kg \[^14^C\]teneligliptin. The absorbed radioactivity was rapidly distributed to tissues throughout the body, and the maximum tissue concentration was observed at 0.5 h after administration in all tissues except for the testis, epididymis, cecum and large intestine. The maximum tissue concentration was reached at 5 h in the testis, epididymis and cecum, and at 12 h in the large intestine. The plasma concentrations of radioactivity decreased over time with a *t* ~1/2~ of 6.5 h, and radioactivity was undetectable at 72 h after administration. High radioactivity concentrations were detected in the kidney and liver aside from the gastrointestinal tract. The *t* ~1/2~ was 68.3 and 69.0 h in the kidney and liver, respectively. At 168 h after administration, the radioactivity concentration was 13% of the maximum concentration in the kidney, compared with ≤ 3% of the maximum concentration in other tissues.

![Tissue radioactivity concentration--time profiles (ng eq/g) in SD rats after a single oral dose of 1 mg/kg \[^14^C\]teneligliptin. Four SD rats were sampled at each time point](BDD-37-142-g003){#bdd2003-fig-0003}

###### 

Concentration of radioactivity in tissues after a single oral dose of 1 mg/kg \[^14^C\]teneligliptin in SD rats

  Tissue                                                   Concentration of radioactivity (ng eq/ml or g)[a](#bdd2003-note-0007){ref-type="fn"}   *t* ~1/2~ (h)[b](#bdd2003-note-0008){ref-type="fn"}                                                                                                    
  -------------------------------------------------------- -------------------------------------------------------------------------------------- ----------------------------------------------------- ------------------------ ------------------------ ----------------------- ---------------------- ------
  Blood                                                    209.9 ± 57.1 (0.8)                                                                     29.9 ± 13.7 (0.8)                                     9.3 ± 2.1 (0.9)          3.9 ± 0.4 (0.9)          N.D. (N.C.)             0.6 ± 0.7 (N.C.)       6.7
  Plasma                                                   266.5 ± 74.9 (1.0)                                                                     37.2 ± 17.3 (1.0)                                     10.0 ± 2.1 (1.0)         4.5 ± 0.3 (1.0)          N.D. (N.C.)             N.D. (N.C.)            6.5
  Brain                                                    24.4 ± 5.3 (0.1)                                                                       7.7 ± 2.6 (0.2)                                       3.3 ± 0.7 (0.3)          N.D. (N.C.)              N.D. (N.C.)             N.D. (N.C.)            4.1
  Pituitary                                                1412.4 ± 316.0 (5.3)                                                                   406.6 ± 198.9 (10.9)                                  149.8 ± 20.6 (15.0)      68.6 ± 11.7 (15.2)       13.0 ± 15.0 (N.C.)      N.D. (N.C.)            17.8
  Medulla oblongata                                        26.6 ± 6.0 (0.1)                                                                       9.3 ± 4.5 (0.3)                                       3.0 ± 0.3 (0.3)          N.D. (N.C.)              N.D. (N.C.)             N.D. (N.C.)            3.7
  Eyeball                                                  107.9 ± 27.9 (0.4)                                                                     39.0 ± 11.9 (1.0)                                     17.4 ± 3.8 (1.7)         8.4 ± 0.9 (1.9)          1.5 ± 0.3 (N.C.)        N.D. (N.C.)            17.6
  Submaxillary gland                                       1009.9 ± 265.5 (3.8)                                                                   309.9 ± 62.2 (8.3)                                    123.7 ± 24.6 (12.4)      78.5 ± 12.3 (17.4)       18.0 ± 5.0 (N.C.)       6.9 ± 2.5 (N.C.)       43.6
  Thyroid                                                  826.4 ± 164.2 (3.1)                                                                    279.2 ± 83.8 (7.5)                                    124.3 ± 25.9 (12.4)      55.2 ± 7.4 (12.3)        N.D. (N.C.)             N.D. (N.C.)            8.3
  Spinal cord                                              28.2 ± 7.8 (0.1)                                                                       11.4 ± 5.8 (0.3)                                      4.9 ± 2.4 (0.5)          1.6 ± 1.1 (0.4)          N.D. (N.C.)             N.D. (N.C.)            6.8
  Thymus                                                   538.8 ± 138.4 (2.0)                                                                    298.8 ± 61.8 (8.0)                                    181.8 ± 19.4 (18.2)      132.1 ± 3.9 (29.4)       37.5 ± 8.1 (N.C.)       10.6 ± 3.3 (N.C.)      41.0
  Heart                                                    454.0 ± 85.0 (1.7)                                                                     118.7 ± 34.6 (3.2)                                    56.6 ± 8.9 (5.7)         30.6 ± 2.7 (6.8)         6.3 ± 1.1 (N.C.)        N.D. (N.C.)            19.5
  Lung                                                     1938.4 ± 456.7 (7.3)                                                                   714.7 ± 116.7 (19.2)                                  500.7 ± 40.2 (50.1)      323.6 ± 46.7 (71.9)      71.3 ± 12.9 (N.C.)      16.9 ± 5.9 (N.C.)      35.2
  Liver                                                    4686.7 ± 932.3 (17.6)                                                                  1753.2 ± 130.4 (47.1)                                 814.1 ± 68.7 (81.4)      389.5 ± 49.5 (86.6)      250.2 ± 21.8 (N.C.)     92.4 ± 17.2 (N.C.)     69.0
  Adrenal                                                  1221.7 ± 289.0 (4.6)                                                                   323.7 ± 90.7 (8.7)                                    177.0 ± 22.7 (17.7)      100.4 ± 8.8 (22.3)       20.5 ± 4.3 (N.C.)       6.5 ± 4.5 (N.C.)       38.5
  Kidney                                                   4568.2 ± 609.1 (17.1)                                                                  3292.8 ± 76.8 (88.5)                                  2872.1 ± 419.4 (287.2)   2637.8 ± 410.3 (586.2)   1548.5 ± 192.3 (N.C.)   606.1 ± 203.2 (N.C.)   68.3
  Spleen                                                   1377.2 ± 292.1 (5.2)                                                                   510.7 ± 68.2 (13.7)                                   312.9 ± 31.8 (31.3)      217.7 ± 21.3 (48.4)      62.4 ± 7.3 (N.C.)       17.0 ± 4.3 (N.C.)      40.5
  Pancreas                                                 1253.9 ± 341.0 (4.7)                                                                   298.9 ± 83.1 (8.0)                                    107.8 ± 22.6 (10.8)      50.8 ± 1.2 (11.3)        8.3 ± 1.8 (N.C.)        3.4 ± 0.9 (N.C.)       39.8
  Prostate                                                 478.6 ± 167.1 (1.8)                                                                    169.0 ± 53.9 (4.5)                                    76.7 ± 18.8 (7.7)        38.6 ± 3.3 (8.6)         6.1 ± 1.3 (N.C.)        2.2 ± 0.6 (N.C.)       37.3
  Testis                                                   68.5 ± 21.6 (0.3)                                                                      128.2 ± 41.8 (3.4)                                    49.6 ± 10.4 (5.0)        18.7 ± 2.4 (4.2)         8.3 ± 10.2 (N.C.)       N.D. (N.C.)            26.5
  Epididymis                                               232.5 ± 61.7 (0.9)                                                                     352.5 ± 76.0 (9.5)                                    259.9 ± 44.4 (26.0)      167.6 ± 35.4 (37.2)      44.9 ± 3.8 (N.C.)       11.2 ± 3.3 (N.C.)      38.1
  Seminal vesicle                                          329.0 ± 105.4 (1.2)                                                                    133.8 ± 57.4 (3.6)                                    51.0 ± 6.3 (5.1)         18.7 ± 4.4 (4.2)         1.7 ± 2.0 (N.C.)        N.D. (N.C.)            12.7
  Aorta                                                    488.7 ± 78.4 (1.8)                                                                     99.0 ± 46.0 (2.7)                                     35.7 ± 16.7 (3.6)        15.4 ± 5.2 (3.4)         N.D. (N.C.)             N.D. (N.C.)            7.3
  Skin                                                     366.3 ± 77.9 (1.4)                                                                     199.1 ± 47.5 (5.4)                                    99.2 ± 14.6 (9.9)        55.2 ± 2.9 (12.3)        18.9 ± 1.6 (N.C.)       9.3 ± 3.3 (N.C.)       59.5
  Skeletal muscle                                          242.5 ± 66.9 (0.9)                                                                     46.7 ± 20.1 (1.3)                                     16.7 ± 2.4 (1.7)         7.9 ± 1.1 (1.8)          N.D. (N.C.)             N.D. (N.C.)            7.7
  Bone                                                     118.7 ± 22.2 (0.4)                                                                     52.3 ± 19.9 (1.4)                                     23.8 ± 7.5 (2.4)         11.8 ± 3.1 (2.6)         3.4 ± 0.9 (N.C.)        0.6 ± 0.7 (N.C.)       34.1
  Bone marrow                                              880.0 ± 223.0 (3.3)                                                                    289.9 ± 63.9 (7.8)                                    159.2 ± 15.7 (15.9)      98.6 ± 7.0 (21.9)        30.7 ± 5.7 (N.C.)       7.0 ± 4.9 (N.C.)       38.6
  Fat                                                      120.4 ± 28.3 (0.5)                                                                     33.3 ± 9.7 (0.9)                                      17.2 ± 2.8 (1.7)         7.8 ± 1.2 (1.7)          2.2 ± 1.5 (N.C.)        N.D. (N.C.)            21.7
  Brown fat                                                501.8 ± 157.5 (1.9)                                                                    134.2 ± 55.8 (3.6)                                    57.6 ± 10.4 (5.8)        26.9 ± 2.8 (6.0)         7.5 ± 1.3 (N.C.)        3.0 ± 1.1 (N.C.)       48.1
  Mesenteric lymph nodes                                   853.9 ± 176.8 (3.2)                                                                    269.9 ± 46.4 (7.3)                                    128.0 ± 21.0 (12.8)      77.9 ± 9.6 (17.3)        22.6 ± 3.3 (N.C.)       9.2 ± 2.2 (N.C.)       49.3
  Stomach                                                  2193.4 ± 953.1 (8.2)                                                                   243.1 ± 117.9 (6.5)                                   47.6 ± 12.0 (4.8)        21.7 ± 1.7 (4.8)         4.2 ± 1.5 (N.C.)        1.3 ± 1.6 (N.C.)       37.5
  Small intestine                                          4476.6 ± 1778.8 (16.8)                                                                 2688.4 ± 1240.2 (72.3)                                344.0 ± 52.7 (34.4)      179.7 ± 29.3 (39.9)      57.8 ± 11.4 (N.C.)      34.8 ± 13.0 (N.C.)     65.8
  Cecum                                                    332.4 ± 101.9 (1.2)                                                                    1103.8 ± 713.4 (29.7)                                 627.2 ± 294.5 (62.7)     123.4 ± 23.7 (27.4)      12.8 ± 2.7 (N.C.)       5.6 ± 2.5 (N.C.)       35.3
  Large intestine [c](#bdd2003-note-0009){ref-type="fn"}   416.0 ± 110.3 (1.6)                                                                    342.6 ± 160.7 (9.2)                                   475.8 ± 195.4 (47.6)     120.7 ± 13.9 (26.8)      19.6 ± 3.5 (N.C.)       7.4 ± 3.3 (N.C.)       38.4

Data are expressed as the mean ± standard deviation of four animals. The values in parentheses represent the ratio of the tissue concentration to the plasma concentration (*K* ~p~) calculated from the mean value.

Average lower limit of quantification (plasma) ≈ 2 ng eq./ml.

The *t* ~1/2~ for the tissue concentration was calculated using the mean value at the last three quantifiable time‐points after administration.

Excluding the cecum.

N.D., not determined; N.C., not calculated.

Whole‐body autoradiography in SD rats (study 2) {#bdd2003-sec-0015}
-----------------------------------------------

Figure [4](#bdd2003-fig-0004){ref-type="fig"} shows a whole‐body autoradiogram of a fasted SD rat given a single oral dose of 1 mg/kg \[^14^C\]teneligliptin. At 0.5 h after administration, the radioactivity was rapidly distributed to tissues throughout the body, and the concentration was greatest in the kidney and liver, as well as the gastrointestinal tract. In the kidney, radioactivity was mainly detected in the outer layer of the medulla, with lower concentrations in the cortex and renal pelvis. At 168 h after administration, the kidney showed a relatively high level of radioactivity. A low level of radioactivity was detected in the liver, and negligible radioactivity was detected in the other tissues examined. In the kidney, the radioactivity was mainly detected in the outer layer of the medulla at all time‐points.

![Whole‐body autoradiograms of one SD rat after a single oral dose of 1 mg/kg \[^14^C\]teneligliptin](BDD-37-142-g004){#bdd2003-fig-0004}

Whole‐body autoradiography in wild‐type or DPP‐4‐deficient rats (study 3) {#bdd2003-sec-0016}
-------------------------------------------------------------------------

Figures [5](#bdd2003-fig-0005){ref-type="fig"}, [6](#bdd2003-fig-0006){ref-type="fig"} show whole‐body autoradiograms after a single oral administration of \[^14^C\]teneligliptin at 1 mg/kg to fasted wild‐type (Figure [5](#bdd2003-fig-0005){ref-type="fig"}) and DPP‐4‐deficient (Figure [6](#bdd2003-fig-0006){ref-type="fig"}) rats. The radioactivity concentration--time profiles in the kidney, liver, lung, heart and pancreas are shown in Figure [7](#bdd2003-fig-0007){ref-type="fig"}. At 0.5 h after administration, the radioactivity was rapidly distributed to most organs in both strains, especially the kidney and liver, in addition to the gastrointestinal tract. The tissue distribution was similar in both strains, except for the kidney, where the radioactivity concentration in the DPP‐4‐deficient rats was approximately 45% of that in wild‐type rats at 0.5 h after dosing. The radioactivity concentration--time profiles in the heart and pancreas were similar in both strains, whereas those in the kidney, liver and lung indicated greater concentrations for a longer duration in wild‐type rats than in DPP‐4‐deficient rats. The *t* ~1/2~ values for the radioactivity concentrations in the kidney, liver and lung were 257, 41.9 and 13.6 h, respectively, in wild‐type rats compared with 12.6 h, 13.4 h and undeterminable, respectively, in DPP‐4‐deficient rats. At 48 h after administration, however, the autoradiograms obtained for the DPP‐4‐deficient rat showed that the radioactivity concentrations in most tissues were low or undetectable, whereas radioactivity was detectable in almost all tissues, except for the pituitary gland, thyroid, heart and brown adipose tissue, in wild‐type rats. The autoradiograms of the kidney at all time‐points revealed the presence of radioactivity in the outer layer of the medulla in wild‐type rats, which was similar to that in SD rats, but not DPP‐4‐deficient rats.

![Whole‐body autoradiograms of one wild‐type Fischer rat after a single oral dose of 1 mg/kg \[^14^C\]teneligliptin](BDD-37-142-g005){#bdd2003-fig-0005}

![Whole‐body autoradiograms of one DPP‐4‐deficient rat after a single oral dose of 1 mg/kg \[^14^C\]teneligliptin](BDD-37-142-g006){#bdd2003-fig-0006}

![Tissue radioactivity concentration--time profiles (ng eq/g) in wild‐type Fischer rats or DPP‐4‐deficient rats after a single oral dose of 1 mg/kg \[^14^C\]teneligliptin. One SD rat was sampled at each time point](BDD-37-142-g007){#bdd2003-fig-0007}

Metabolite profiles in plasma and kidney (study 4) {#bdd2003-sec-0017}
--------------------------------------------------

Figures [8](#bdd2003-fig-0008){ref-type="fig"}, [9](#bdd2003-fig-0009){ref-type="fig"} show the representative radiochromatograms of plasma at 0.5 and 5 h and of the kidney at 0.5, 24 and 72 h after a single dose of 1 mg/kg \[^14^C\]teneligliptin in fasted SD rats. Teneligliptin and its metabolites in plasma or kidney were identified by comparing their HPLC‐ultraviolet chromatographic retention times with those of the reference standards. Teneligliptin was the most abundant radioactive component in plasma and kidney at all of the time‐points measured. M1 (thiazolidine‐1‐oxide metabolite) was detected at low levels in plasma at 0.5 h after administration. The other metabolites were not detected in plasma. Only M4 (hydroxymethyl metabolite) was detected in trace concentrations in the kidney.

![Representative HPLC radiochromatograms of plasma levels (cpm) from SD rats after a single oral dose of 1 mg/kg \[^14^C\]teneligliptin. Two or four SD rats were sampled at each time point](BDD-37-142-g008){#bdd2003-fig-0008}

![Representative HPLC radiochromatograms of kidney levels (cpm) from SD rats after a single oral dose of 1 mg/kg \[^14^C\]teneligliptin. Two or four SD rats were sampled at each time point](BDD-37-142-g009){#bdd2003-fig-0009}

Discussion {#bdd2003-sec-0018}
==========

This study showed that after an oral dose of \[^14^C\]teneligliptin, radioactivity corresponding to this molecule was rapidly distributed throughout the whole body of rats. Our findings suggest that most radioactivity distributed to these tissues corresponds to the unchanged drug. The volume of distribution (*V* ~ss~: 8.9 l/kg, Table [1](#bdd2003-tbl-0001){ref-type="table-wrap"}) based on the plasma concentration--time profile of the unchanged drug after the intravenous administration of teneligliptin to rats was greater than the extracellular fluid volume (approximately 0.3 l/kg) [27](#bdd2003-bib-0027){ref-type="ref"}, consistent with a broad tissue distribution profile. Similar *V* ~ss~ values were obtained after intravenous administration of other DPP‐4 inhibitors (range, 3.5--50.3 l/kg), with the exception of anagliptin (0.68 l/kg), which indicated that most DPP‐4 inhibitors have a high tissue distribution (Table [1](#bdd2003-tbl-0001){ref-type="table-wrap"}). After oral administration of \[^14^C\]teneligliptin to SD rats, it was predominantly distributed to the kidney and liver, in addition to the gastrointestinal tract, and high concentrations were also detected in the lung, spleen and pituitary gland. Of note, the *t* ~1/2~ values for radioactivity in the kidney and liver were approximately 10 times higher than the plasma *t* ~1/2~, which indicates that teneligliptin is slowly eliminated from the kidney and liver. Similar organ‐specific elimination patterns were also observed in wild‐type Fischer rats, which were used as a control for the DPP‐4‐deficient rats. Notably, the *t* ~1/2~ values for the elimination of \[^14^C\]teneligliptin radioactivity were much higher in the kidney and liver (257 and 41.9 h, respectively) than in other tissues (Figure [7](#bdd2003-fig-0007){ref-type="fig"}). The *t* ~1/2~ values for the elimination of radioactivity from the kidney and liver were much lower in DPP‐4‐deficient rats (12.6 and 13.4 h, respectively). Additionally, there were no marked differences in the radioactivity concentration--time profile in the heart and pancreas between wild‐type and DPP‐4‐deficient rats. Mentlein previously reported that tissue DPP‐4 activity was greatest in the kidney, followed by the lung, adrenal gland, jejunum and liver, and was lowest in the heart and pancreas [28](#bdd2003-bib-0028){ref-type="ref"}. These results suggest that tissue DPP‐4 is involved in the tissue distribution of teneligliptin.

In this study, the radioactivity in the kidney in wild‐type Fischer rats was greatest in the outer layer of the renal medulla followed by the renal cortex, and was lowest in the renal pelvis, consistent with the distribution detected in SD rats. By contrast, the radioactivity was not specifically distributed to the outer layer of the renal medulla in DPP‐4‐deficient rats. In a study by Fukasawa *et al*., immunostaining revealed that DPP‐4 expression was greatest around the outer layer of the renal medulla in the rat kidney [29](#bdd2003-bib-0029){ref-type="ref"}. Thus, the distribution of DPP‐4 expression in the kidney was consistent with the distribution of radioactivity after administration of \[^14^C\]teneligliptin, and most radioactivity in the kidney was present as unchanged teneligliptin (Figure [9](#bdd2003-fig-0009){ref-type="fig"}). These findings suggest that teneligliptin has a high affinity for DPP‐4 in the kidney.

The tissue‐to‐plasma ratio of radioactivity (*K* ~p~) for all of the currently marketed DPP‐4 inhibitors tends to be greater in the kidney, liver and lung than in other organs, and linagliptin and teneligliptin had higher renal *K* ~p~ values (around 100) (Table [3](#bdd2003-tbl-0003){ref-type="table-wrap"}). The renal *K* ~p~ values for saxagliptin and anagliptin were approximately 5 and 7, respectively. Although the *V* ~ss~ values suggest that DPP‐4 inhibitors show high tissue distribution, the extent of drug distribution in the kidney differed markedly among DPP‐4 inhibitors.

###### 

Tissue‐to‐plasma (or blood) ratio (*K* ~p~) of radioactivity after an oral dose of radioisotope‐labeled DPP‐4 inhibitors to rats

  Drug \[Reference\]                                     Kidney   Lung   Liver   Heart   Pancreas   Dose (mg/kg)   Sampling time (h)
  ------------------------------------------------------ -------- ------ ------- ------- ---------- -------------- -------------------
  Alogliptin [22](#bdd2003-bib-0022){ref-type="ref"}     29.7     8.6    17.3    2.36    4.94       3              4
  Anagliptin [21](#bdd2003-bib-0021){ref-type="ref"}     6.71     1.50   4.36    0.74    0.81       10             6
  Linagliptin [23](#bdd2003-bib-0023){ref-type="ref"}    113      11.1   42.3    4.78    --         2              4
  Saxagliptin [24](#bdd2003-bib-0024){ref-type="ref"}    5.29     1.32   32.3    0.55    1.01       20             4
  Sitagliptin [25](#bdd2003-bib-0025){ref-type="ref"}    14.7     9.09   22.0    2.73    5.69       5              4
  Teneligliptin                                          88.5     19.2   47.1    3.20    8.00       1              5
  Vildagliptin [26](#bdd2003-bib-0026){ref-type="ref"}   13.4     2.60   13.6    1.48    3.29       100            4

The distribution of radioactivity in the kidney after administration of \[^14^C\]linagliptin to rats in a prior study [30](#bdd2003-bib-0030){ref-type="ref"} was similar to that obtained with \[^14^C\]teneligliptin in our study. The authors of the earlier study proposed that binding to DPP‐4 is an important contributor to the high concentration in the kidney. Additionally, a non‐linear tissue distribution of linagliptin was observed after it was intravenously administered to rats at doses above 3 mg/kg [23](#bdd2003-bib-0023){ref-type="ref"}. These results were attributed to the saturation of its binding to DPP‐4.

In general, the extent of tissue distribution for basic compounds is dependent on log*P* and pKa, in the absence of active uptake via transporters and specific intracellular binding [31](#bdd2003-bib-0031){ref-type="ref"}. Because the pKa values of most DPP‐4 inhibitors are similar, it seems likely that log*P* values may be an important factor involved in their tissue distributions (Table [1](#bdd2003-tbl-0001){ref-type="table-wrap"}). In fact, the *C*log*P* was highest for teneligliptin (2.24) followed by linagliptin (1.91).

Nabeno *et al*. compared the binding modes of teneligliptin and linagliptin with DPP‐4 by x‐ray crystallography [10](#bdd2003-bib-0010){ref-type="ref"}. As shown in Table [1](#bdd2003-tbl-0001){ref-type="table-wrap"}, linagliptin and teneligliptin bind via distinct modes. Linagliptin binds to the S~1~, S~2~, S'~1~ and S'~2~ subsites, whereas teneligliptin binds to S~1~, S~2~ and S~2~ extensive subsites with high affinity owing to a considerably rigid structure. Because the physiological significance of this difference is unknown, further investigations are needed.

DPP‐4 is also expressed as a membrane‐bound form in many tissues, including the kidney and liver. Because DPP‐4 is also involved in inflammation, tissue injury and oxidative stress, DPP‐4 inhibitors may have protective effects in the kidney, liver and vascular tissue, in addition to their glucose‐lowering effects [32](#bdd2003-bib-0032){ref-type="ref"}, [33](#bdd2003-bib-0033){ref-type="ref"}, [34](#bdd2003-bib-0034){ref-type="ref"}, [35](#bdd2003-bib-0035){ref-type="ref"}, [36](#bdd2003-bib-0036){ref-type="ref"}. The kidney has the highest DPP‐4 activity of all tissues, and DPP‐4 expression was up‐regulated in animal models of diabetic nephropathy and in human diabetes patients [36](#bdd2003-bib-0036){ref-type="ref"}. Although the effects of teneligliptin on the kidney have not been clearly demonstrated, other DPP‐4 inhibitors were reported to show a renoprotective effect. Despite the weak glucose‐lowering effect of DPP‐4 inhibitors in a type 1 diabetes model, DPP‐4 inhibitors have generally improved renal function in this model. In clinical use, DPP‐4 inhibitors were reported to reduce albuminuria independent of the reduction in hemoglobin A1c (a marker of blood glucose control) [37](#bdd2003-bib-0037){ref-type="ref"}. These results suggested that DPP‐4 inhibitors have a renoprotective effect independent of blood glucose control. Although the mechanism is not fully understood, inhibition of interactions between DPP‐4 and integrin β1 by DPP‐4 inhibitors is an important factor for its antifibrotic effect in diabetic kidneys [38](#bdd2003-bib-0038){ref-type="ref"}. Regarding vascular protection, acetylcholine‐induced vascular relaxation in a ZDF rat model was significantly stronger with linagliptin compared with sitagliptin, although both drugs produced equivalent decreases in blood glucose. Vascular malondialdehyde, an oxidative stress marker, and vascular DPP‐4 activity were also attenuated by these drugs, with linagliptin producing significantly greater attenuation than sitagliptin. The author of this study suggested that the difference in effect between these drugs might be related to the vascular tissue distribution properties; thus, the vascular inhibition of DPP‐4 may be important for vascular protection [39](#bdd2003-bib-0039){ref-type="ref"}. Teneligliptin attenuated endothelial dysfunction through the up‐regulation of eNOS and decreased TNF‐α expression in the aorta in an SHRcp model [40](#bdd2003-bib-0040){ref-type="ref"}. Although the role of tissue DPP‐4 should be further investigated, differences in the tissue distributions of DPP‐4 inhibitors might be related to differences in their pleiotropic effects. In our study, teneligliptin showed a high affinity for the kidney and other organs with high DPP‐4 expression. Therefore, teneligliptin may have protective effects on these organs independent of its blood glucose‐lowering activity.

In conclusion, all DPP‐4 inhibitors are predominantly distributed to the kidney, liver and lung, all of which show high DPP‐4 expression. Marked differences were also found in the extent of tissue distribution for these DPP‐4 inhibitors. Teneligliptin showed greater distribution, especially in the kidney and the liver, than other DPP‐4 inhibitors. Further studies are needed to examine the relationship between the tissue distribution of DPP‐4 inhibitors and their pleiotropic effects by inhibiting DPP‐4.
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